Metabolic and Immunological Features of the Failing Islet-Transplanted Patient-Reference-Cited by-同舟云学术

Metabolic and Immunological Features of the Failing Islet-Transplanted Patient

Published:2008-03-01 Issue:3 Volume:31 Page:436-438
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Fiorina Paolo¹²,Vergani Andrea¹²,Petrelli Alessandra¹,D'Addio Francesca²,Monti Lucilla¹,Abdi Reza²,Bosi Emanuele¹,Maffi Paola¹,Secchi Antonio¹³

Affiliation:

1. Department of Medicine, San Raffaele Scientific Institute, Milan, Italy

2. Transplantation Research, Children's Hospital/Brigham and Women's Hospital, Boston, Massachusetts

3. Università Vita e Salute-San Raffaele, Milan, Italy

Abstract

OBJECTIVE—This retrospective study was designed to identify metabolic and immune predictors of early islet allograft failure. RESEARCH DESIGN AND METHODS—We measured several metabolic and immunological markers at the time of pretransplant and several time points posttransplantation in 17 patients with long-term functioning graft (long fx) and 20 patients with short-term functioning graft (short fx). RESULTS—The short fx group showed higher insulin resistance, altered proinsulin processing, lower soluble interleukin-2 receptor (sIL-2r) (marker of T-cell activation), and higher soluble FasL (marker of apoptosis) during the entire follow-up, particularly at time of failure. CONCLUSIONS—Patients who experienced an early failure of islet allograft showed specific metabolic and immunological signs long before islet failure.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/31/3/436/598696/zdc00308000436.pdf

Reference24 articles.

1. Ricordi C: Islet transplantation: a brave new world. Diabetes 52:1595–1603, 2003

2. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 50:710–719, 2001

3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069, 2005

4. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238, 2000

5. Shapiro AM, Nanji SA, Lakey JR: Clinical islet transplant: current and future directions towards tolerance. Immunol Rev 196:219–236, 2003

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The β Cell in Diabetes: Integrating Biomarkers With Functional Measures;Endocrine Reviews;2021-06-28

2. Autoreactive T cell profiles are altered following allogeneic islet transplantation with alemtuzumab induction and re‐emerging phenotype is associated with graft function;American Journal of Transplantation;2020-09-19

3. Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients;Transplantation;2020-05-18

4. Procedure-related and medical complications in and after intraportal islet transplantation;Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas;2020

5. IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants;Journal of Molecular Endocrinology;2018-02